The Lupus Inhibitor: A Study of Its Heterogeneity

Summary

The plasmas of six patients with prolonged activated partial thromboplastin times were studied in detail. In five of the six, the Russell’s viper venom and prothrombin times were likewise prolonged. Five of the patients had documented systemic lupus erythematosus; one lacked the necessary criteria for this diagnosis. On quantitation, factor XI was decreased in all six; factors X and XII were diminished in five of the six. When tested for inhibitory activity, plasma from each of the patients prolonged the celite eluate inhibition test for factor XII and/or XI inhibition. In the formation of the X_a-V-phospholipid-Ca²⁺ complex (prothrombinase), factors X and X_a were inhibited to a greater degree than factor V or the phospholipid. Finally, each plasma was isofocused, the inhibitory fractions were identified and the clotting factor specificity of each inhibitory peak was determined.Fractions inhibitory against factors XI and XII isofocused with the IgG in each patient’s plasma. Based on the data presented from these six patients, the “lupus inhibitor” is in fact a heterogeneous collection of inhibitors directed against factors XII, XI and X rather than a homogeneous entity.

Keywords

Lupus inhibitor - Isofocusing - Factor X inhibitor - Factor XI inhibitor - Factor XII inhibitor

• References

• 1 Frick PG. Acquired circulating anticoagulant in systemic“collagen disease”. Autoimmune thromboplastin deficiency Blood 1955; 10: 691-706
• 2 Schieider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
• 3 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. In: Progress in Hemostasis and Thrombosis (T Spaet). Vol 1 pp 75-95 1972. Grune and Stratton; New York, N. Y:
• 4 Lechner K. A new type of coagulation inhibitor. Thrombos Diathes Haemorrh 1969; 21: 482-499
• 5 Thiagarajan P, Shapiro SS. Lupus anticoagulants are antibodies reactive against phospholipids. Circulation (Abstracts) 1980; Part II 62: 279 Abstract Number 1069
• 6 Lee SL, Sanders M. A disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest 1955; 34: 1814-1822
• 7 Laurell A, Nilsson IM. Hyperglobulinemia, circulating anticoagulant and biologic false positive Wasserman reaction. J Lab Clin Med 1957; 49: 694-707
• 8 Bowie EW, Thompson JH, Cascuzzi PA, Owen CA. Thrombosis in SLE despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
• 9 Mayer G, Mayer S, Waitz R. Anticoagulant circulant associé à une thrombopénie. Hémostase 1967; 5: 21-36
• 10 Veltkamp H, Kerkhoven P, Loeliger EA. Circulating anticoagulant in disseminated lupus erythematosus: Proposed mode of action. Haemostasis 1974; 2: 25
• 11 Lechner K. Acquired inhibitors in non-hemophilic patients. Haemostasis 1974; 3: 65-93
• 12 Gobbi F, Stefanini M. Circulating anti-AHG anticoagulant in a patient with lupus erythematosus disseminatus. Effect of a cephalin complex in vivo Acta haematol 1962; 28: 155-162
• 13 Regan MG, Lackner H, Karpatkin S. Platelet function and coagulation profile in lupus erythematosus. Ann Int Med 1974; 81: 462-468
• 14 Robboy SJ, Lewis EJ, Schur PH, Colman RW. Circulating anticoagulants and clinical response to factor VIII concentrates. Am J Med 1970; 49: 742
• 15 Okpara RA, Carabello JA, Day JH. Spurious prolongation of the activated partial thromboplastin time. Thromb Haemostas 1977; 38: 900-908
• 16 Castro O, Färber LR, Clyne LP. Circulating anticoagulant against factors IX and XI in systemic lupus erythematosus. Ann Int Med 1972; 77: 543-548
• 17 Bonnin JA, Cohen AK, Hicks ND. Coagulation defects in a case of systemic lupus erythematosus with thrombocytopenia. Br J Haematol 1956; 2: 168-179
• 18 Margolis A JR, Jackson DP, Ratnoff OD. Circulating anticoagulants: A study of 40 cases and review of the literature. Medicine 1961; 40: 145-202
• 19 Aberg H, Nilsson IM. Recurrent thrombosis in a young man with a circulating anticoagulant against IX and XI in SLE. Acta med Scand 1972; 192: 419-425
• 20 Sánchez-Medal L, Lisker R, López ET. Unusual circulating anticoagulant in a patient with systemic lupus erythematosus. Acta haematol 1963; 29: 117-122
• 21 Largo R, Sigg P, Felten Avon, Straub PW. Erworbener Factor IX–Hemmkörper bei einem nicht-hämophilen Patienten mit Autoimmun-krankheit. Schweiz med Wschr 1972; 102: 1612-1613
• 22 Breckenridge RJ, Ratnoff OD. Studies on the site of action of a circulating anticoagulant in disseminated lupus erythematosus. Am J Med 1963; 35: 813-819
• 23 Leone G, Accorra F, Boni P. Circulating anticoagulant against factor XI and thrombocytopenia with platelet aggregation inhibition in systemic lupus erythematosus. Acta haematol 1977; 58: 240-245
• 24 Krieger H, Leddy JP, Breckenridge RT. Studies on a circulating anticoagulant in systemic lupus.. Evidence of inhibition of the function of activated plasma thromboplastin antecedent (factor XI_a) Blood 1975; 46: 189-197
• 25 Cronberg S, Nilsson IM. Circulating anticoagulant against factors XI and XII together with spontaneous platelet aggregation. Scand J Haematol 1973; 10: 309-314
• 26 Di Sabatino CA, Clyne LP, Malawista SE. A circulating anticoagulant directed against factor XI_ain systemic lupus erythematosus. Arthritis Rheum 1979; 22: 1135-1138
• 27 Gandolfo GM, Afeltra A, Amoroso A, Biancollella F, Ferri GM. Circulating anticoagulant against factor XII and platelet antibodies in systemic lupus erythematosus. Acta Haematol 1977; 57: 135-142
• 28 Rodman GP. (ed) Preliminary criteria for the classification of systemiclupus erythematosus. In: Primer on the Rheumatic Diseases, Edition 7 American Rheumatism Association Section of the Arthritis Foundation 1973; 139
• 29 Coots MC, Muhleman AF, Glueck HI. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978; 4: 193-206
• 30 Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913; 145: 495-503
• 31 Stander RW, Flessa HC, Glueck HI, Kisker CT. Changes in maternal coagulation factors after intra-amniotic injection of hypertonic saline. Obstet Gynecol 1971; 37: 660-666
• 32 Denson K WE, Borrett R, Biggs R. The specific assay of prothrombin using Taipan snake venom. Br J Haematol 1971; 21: 219-226
• 33 Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951; 37: 316-320
• 34 Mitchell GA, Hudson P, Huseby RM, Pochron SP, Garguilo A. Fluorescent substrate assay for antithrombin HI. Thromb Res 1978; 12: 219-225
• 35 Bnnkhous KM, Graham JE, Cooper HA, Allain JP, Wagner RH. Assay of von Willebrand factor in von Willebrand’s disease and hemophilia: Use of a macroscopic platelet aggregation test. Thromb Res 1975; 6: 267-272
• 36 Nossel HL. The Contact Phase of Blood Coagulation. F. A. Davis Company; Philadelphia: 1964: 45
• 37 Waaler BA. Contact activation in the intrinsic blood clotting system. Scand J Clin Lab Invest 1959; 11 Suppl (Suppl. 37) 56
• 38 Bell WN, Alton HG. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature 1954; 174: 880-881
• 39 Malhotra OP, Carter JR. A simple method for preparing substrate for factor X assay. Fed Proc 1966; 25: 256
• 40 Rodman Jr NF, Barrow EM, Graham JB. Diagnosis and control of hemophilloid states with the partial thromboplastin time (PTT) test. Am J Clin Pathol 1958; 29: 525-538
• 41 Glueck HI, Wachman J. A TAMe micromethod for the measurement of esterase prothrombin. Am J Clin Pathol 1970; 54: 239-248
• 42 Firkin BG, Booth P, Hendrix L, Howard MA. Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant. Am J Hematol 1978; 5: 81-92
• 43 Schiffman S, Theodor I, Rapaport SI. Separation from Russell’s viper venom of one fraction reacting with factor X and another reacting with factor V. Biochemistry 1969; 8: 1397-1405
• 44 Lindquist PA, Fujikawa K, Davie EW. Activation of bovine IX by a protease from Russell’s viper venom. Fed Proc 1976; 35: 1353
• 45 Seligsohn U, Østerud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems: Roles of activated factor IX, kallikrein and activated factor XII. J Clin Invest 1979; 64: 1056-1065
• 46 Fantl P, Nance MH. An acquired haemorrhagic disease in a female due to an inhibitor of blood coagulation. Med J Aust 1946; 1: 125-128